

Efficacy and Safety of Shatavari for Treatment of Menopausal Symptoms in Women: A Randomized, Double-blind, Three-arm, Parallel, Placebo-controlled Study

NCT06716554

Status	RECRUITING
Phase	Not Applicable
Sponsor	SF Research Institute, Inc.
Enrollment	51 participants

Key Eligibility Criteria

Inclusion (8)

- Menopausal women aged 45 to 65 years with intact uterus and ovaries.
 - Participants who complained of irregular menstrual cycle in the past 12 months, with a forward or postpone of a cycle more 7 days. At least 2 cycles were missing during the past 12 months, or reported menopause for at least 60 days
 - Females with complaints of menopausal symptoms, e.g., hot flash, insomnia, migraine, easy irritation, etc.
 - Body mass index 18-35 kg/m²
 - Subject who has given written informed consent to participate in the study and understand the nature of the study
- ... and 3 more (see full listing online)

Exclusion (15)

- Participants taking any form of herbal extract in the last 3 months before study entry.
 - Participants who are on hormone replacement therapy (HRT) for more than 3 months.
 - Participants with Present active medical, surgical, and gynaecological problems.
 - Participants with a history of alcohol, tobacco dependence, or any substance abuse
 - Participants who had undergone bilateral ovariectomy
- ... and 10 more (see full listing online)

Locations (1 total)

SF Research Institute, Inc., San Francisco, California, United States